eXoZymes (NASDAQ:EXOZ) Shares Up 2.4% - What's Next?

Key Points

• Shares rose about 2.4% to $7.38 on Monday on light volume (≈1,167 shares vs. a 3,177 average), after closing at $7.21 the prior session.
• Analyst sentiment is negative: Weiss Ratings restated a "sell (d-)" and MarketBeat shows a consensus Sell rating.
• The company has a market cap of about $61.99 million and a negative P/E (-9.58); its 50‑day ($9.38) and 200‑day ($11.98) moving averages sit well above the current price while liquidity metrics are strong (current and quick ratios 4.53, debt/equity 0.01).

Shares of eXoZymes Inc. (NASDAQ:EXOZ - Get Free Report) were up 2.4% during trading on Monday . The company traded as high as $7.38 and last traded at $7.38. Approximately 1,167 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 3,177 shares. The stock had previously closed at $7.21.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of eXoZymes in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, eXoZymes currently has a consensus rating of "Sell".

eXoZymes Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 4.53 and a quick ratio of 4.53. The stock has a 50-day moving average price of $9.38 and a 200-day moving average price of $11.98. The company has a market capitalization of $61.99 million, a price-to-earnings ratio of -9.58 and a beta of 2.52.

About eXoZymes

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company's enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.